Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
January 15, 2025 20:00 ET
|
Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
January 15, 2025 16:01 ET
|
Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Yseop Kicks Off 2025 by Strengthening Its Leadership in Generative AI for Life Sciences
January 15, 2025 09:00 ET
|
Yseop
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Yseop, a global leader in Generative AI for life sciences, is starting 2025 with a series of achievements and strategic collaborations that underscore its...
[Latest] Global Clinical Trial Outsourcing Market Size/Share Worth USD 91,210.1 Million by 2033 at a 7.46% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
January 15, 2025 08:10 ET
|
Custom Market Insights
Austin, TX, USA, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Clinical Trial Outsourcing Market Size, Trends and Insights By Services...
KFSHRC Modernizes Biobank Center… Ushering an Era of Personalized Medicine
January 13, 2025 08:08 ET
|
King Faisal Specialist Hospital & Research Centre
KFSHRC Modernizes Biobank Center… Ushering an Era of Personalized Medicine
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
January 13, 2025 07:50 ET
|
Silexion Therapeutics Corp
Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Colombia and Central America
January 13, 2025 07:00 ET
|
George Medicines
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Colombia and Central AmericaBausch Health gains exclusive rights to single-pill triple...
Labviva Secures $25M to Accelerate Product Development and Global Expansion
January 13, 2025 06:25 ET
|
Labviva
Labviva, the leading AI procurement platform for life sciences, today announced the close of its $25 million Series B.
Global Leader in Specialty Therapeutics Selects Kneat to Digitize Validation
January 09, 2025 17:17 ET
|
kneat.com, inc.
Leading European global therapeutics company more than 20,000 people selects Kneat to digitize its validation processes.
H.H.C. Group Successfully Completes URAC Monitoring Validation Review as Independent Review Organization
January 09, 2025 10:02 ET
|
H.H.C. Group
H.H.C. Group Successfully Completes URAC Monitoring Validation Review as Independent Review Organization